Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases

Croatian Medical Journal

Volumn 44, Issue 4, 2003, Pages 418-424

  Levanat, Sonja ^a   Šitum, Mirna ^b   Crnić, Ivana ^a   Marasović, Dujomir ^c   Puizina Ivić, Neira ^c   Pokupčić, Nikola ^a   Musani, Vesna ^a   Komar, Arijana ^a   Kubat, Milovan ^d   Furač, Ivana ^d   Karija Vlahović, Monika ^d   Križanac, Šimun ^d  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c UNIVERSITY HOSPITAL SPLIT   (Croatia)

^d UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Alleles; Genes, p16; Genetic predisposition to disease; Genetic screening; Melanoma

Indexed keywords

PROTEIN P16;

ARTICLE; CANCER SUSCEPTIBILITY; CHROMOSOME 9P; EXON; GENE LOCUS; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HETEROZYGOSITY LOSS; HUMAN; MELANOMA; MUTATION; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

ALLELES; BASE SEQUENCE; BIOPSY, NEEDLE; CROATIA; DNA, NEOPLASM; FEMALE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MALE; MELANOMA; MOLECULAR SEQUENCE DATA; PEDIGREE; PILOT PROJECTS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS;

EID: 0042338505     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol 1996; 34(5 Pt 1):839-47.
2. Rigel DS. Malignant melanoma: incidence issues and their effect on diagnosis and treatment in the 1990s. Mayo Clin Proc 1997;72:367-71.
3. Čiček J. Epidemiology of malignant melanoma [M.S. thesis, in Croatian]. Zagreb: Zagreb University School of Medicine; 1972.
4. Stipić T, Sipić V, Gregurek-Novak T, Čajkovac V, Stipić R. Epidemiologic characteristics of malignant melanoma in the Split district. Acta Dermatovenerol Croat 1998;6:89-94.
5. Giles G, Staples M, McCredie M, Coates M. Multiple primary melanomas: an analysis of cancer registry data from Victoria and New South Wales. Melanoma Res 1995;5:433-8.
6. Greene MH, Fraumeni JF. The hereditary variant of malignant melanoma. New York (NY): Grune & Stratton; 1979.
7. Tucker MA, Fraser MC, Goldstein AM, Elder DE, Guerry D 4th, Organic SM. The risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993;100:350S-355S.
8. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-9p22. Science 1992;258:1148-52.
9. Kumar R, Smeds J, Lundh Rozell B, Hemminki K. Loss of heterozygosity at chromosome 9p21 (INK-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. Melanoma Res 1999;9:138-47.
10. Goldstein AM, Dracopoli NC, Ho EC, Fraser MC, Kearns KS, Baje SJ, et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus on chromosome 1p and evidence for genetic heterogeneity. Am J Hum Genet 1993;52:537-50.
11. Holland EA, Beaton SC, Becker TM, Grulet OM, Peters BA, Rizos H, et al. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 1995;11: 2289-94.
12. Liu L, Lassam NJ, Slingerland JM, Bailey D, Cole D, Jenkins R, et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 1995;11:405-12.
13. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-6.
14. Flores JF, Walker GJ, Glendening JM, Haluska FG, Castresana JS, Rubio MP, et al. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers in sporadic melanoma. Cancer Res 1996;56:5023-32.
15. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
16. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368:753-6.
17. Puig S, Castro J, Ventura PJ, Ruiz A, Ascaso C, Malvehy J, et al. Large deletions of chromosome 9p in cutaneous malignant melanoma identify patients with a high risk of developing metastases. Melanoma Res 2000;10: 231-6.
18. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
19. Goldstein AM, Tucker MA. Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst 1997;89:676-8.
20. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, et al. CDKN2A mutations in multiple primary melanomas. New Engl J Med 1998;338:879-87.
21. Dracopoli NC, Fountain JW. CDKN2A mutations in melanoma. Cancer Surv 1996;26:115-32.
22. Palmieri G, Cossu A, Ascierto PA, Botti G, Strazzullo M, Lissia A, et al. Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. Br J Cancer 2000;83:1707-14.
23. Lewer WF, Schaumberg-Lever G. Melanocyte nevi and malignant melanoma. In: Lewer WS, Schaumberg-Lever G, editors. Histopathology of the skin. Philadelphia (PA): J.B. Lipincott; 1983. p. 681-725.
24. Jeanpierre M. A rapid method for the purification of DNA from blood. Nucleic Acids Res 1987;15:9611.
25. Johnson DR, Levanat S, Bale AE. Direct molecular analysis of archival tumor tissue for loss of heterozygosity. Biotechniques 1995;19:190-2.
26. Mitchell LG, Bodenteich A, Merril CR. Use of silver staining to detect nucleic acids. Methods Mol Biol 1996;58:97-103.
27. MacBeath JR, Harvey SS, Oldroyd NJ. Automated fluorescent DNA sequencing on the ABI PRISM 377. Methods Mol Biol 2001;167:119-52.
28. Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W, et al. Frequent codeletion of p16/MTS1 and p15/WTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 1996;110:1215-24.
29. Matsuda H, Konishi N, Hiasa Y, Hayashi I, Tsuzuki T, Tao M, et al. Alterations of p16/CDKN2A, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 1996;25:232-8.
30. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994;265:415-6.
31. Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, et al. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 1997;6:2061-7.
32. Gonzalgo ML, Bender CM, You EH, Glendening JM, Flores JF, Walker GJ, et al. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 1997;57:5336-47.
33. Ruas M, Peters G. The p16/CDKN2A tumor suppressor and its relative. Biochim Biophys Acta 1998;1378: F115-77.
34. Kannan K, Munirajan AK, Krishnamurthy J, Bhuvarahamurthy V, Mohanprasad BK, Panishankar KH, et al. The p16(INKalpha)/p19(ARF) gene mutations are infrequent and are mutually exclusive to p53 mutations in Indian oral squamous cell carcinomas. Int J Oncol 2000;16: 585-90.
35. Yakobson E, Shemesh P, Azizi E, Winkler E, Lassam N, Hogg D, et al. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. Eur J Hum Genet 2000; 8:590-6.
36. Zurawel RH, Allen C, Wechsler-Reya R, Scott MP, Raffel C. Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer 2000;28:77-81.
37. FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: Analysis of a clinic-based population. Proc Natl Acad Sci U S A 1996;93:8541-5.